WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 75% more annual revenue ($5.65B vs $3.22B). RMD leads profitability with a 27.0% profit margin vs -9.7%. RMD earns a higher WallStSmart Score of 65/100 (C+).

MMED

Avoid

33

out of 100

Grade: F

Growth: 6.7Profit: 3.5Value: 5.0Quality: 6.8
Piotroski: 4/9

RMD

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 5/9Altman Z: 4.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

RMDSignificantly Overvalued (-24.1%)

Margin of Safety

-24.1%

Fair Value

$209.18

Current Price

$224.99

$15.81 premium

UndervaluedFair: $209.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED3 strengths · Avg: 8.7/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.6%8/10

16.6% revenue growth

RMD6 strengths · Avg: 9.2/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Altman Z-ScoreHealth
4.5310/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.1%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.0%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$1.65B8/10

Generating 1.6B in free cash flow

Areas to Watch

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

Free Cash FlowQuality
$-90.00M2/10

Negative free cash flow — burning cash

RMD1 concerns · Avg: 4.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 16.6% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Bear Case : RMD

The primary concerns for RMD are EPS Growth.

Key Dynamics to Monitor

MMED profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

MMED is growing revenue faster at 16.6% — sustainability is the question.

RMD generates stronger free cash flow (1.6B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (65/100 vs 33/100), backed by strong 27.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?